〔Abstract〕 Objective To compare the clinical efficacy and toxicity of FOLFOX, SOX and mFOLFOX6 in the treatment of advanced gastric cancer. Methods A total of 92 patients with advanced gastric cancer admitted to Luoyang Central Hospital Affiliated to Zhengzhou University from May 2020 to October 2021 were selected and divided into group A (31 cases), Group B (31 cases) and Group C (30 cases) according to random drawing method. Patients in group A were treated with FOLFOX regimen, and patients in group B were treated with SOX regimen. Group C was treated with mFOLFOX6 regimen. After 3 cycles of treatment, the clinical efficacy, toxic and side effect [treatment emergent symptom scale (TSEE)], the changes of tumor factor before and after treatment [carcino-embryonic antigen (CEA), carbohydrate antigen (CA) 724) levels and survival of all groups were compared. Results There was no significant difference in the efficacy of solid tumor among all groups (P > 0.05). The scores of behavioral toxicity, laboratory tests and cardiovascular system in group A were higher than those in group B and C, and the scores of nervous system in group B were higher than those in group C, the differences were statistically significant (P < 0.05). After treatment, the levels of CEA and CA724 in all groups were lower than those before treatment, but the difference was not statistically significant (P > 0.05). After half a year's follow-up, the median survival time was 141 d in group A, 127 d in group B and 146.5 d in group C (χ 2 = 0.119, P = 0.905). Conclusion FOLFOX, SOX and mFOLFOX6 all have certain therapeutic effect on advanced gastric cancer, and different therapeutic plans can be selected according to individual differences of patients.